Horizon Pharma plc (HZNP) Boosts FY16 Sales, adj.-EBITDA Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Mizuho Securities Remains Bullish as Horizon Pharma (HZNP) Updates Guidance to Include Krystexxa
January 12, 2016 10:09 AM ESTMizuho Securities reiterated a Buy rating and $36.00 price target on Horizon Pharma (NASDAQ: HZNP) following managements indication that company's $75M guidance raise is only for the inclusion of Krystexxa.
Analyst Irina Koffler commented, "The HSR waiting period on the Crealta acquisition expired on January 11 and... More
